Replimune Group, Inc. (REPL)
13.07
-0.35
(-2.61%)
USD |
NASDAQ |
Oct 12, 16:00
13.07
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Enterprise Value : 1.014B for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 1.014B |
| October 09, 2026 | 1.044B |
| October 08, 2026 | 1.012B |
| October 07, 2026 | 1.025B |
| October 06, 2026 | 1.029B |
| October 05, 2026 | 1.021B |
| October 02, 2026 | 1.014B |
| October 01, 2026 | 1.046B |
| September 30, 2026 | 1.029B |
| September 29, 2026 | 1.008B |
| September 28, 2026 | 971.43M |
| September 25, 2026 | 954.63M |
| September 24, 2026 | 974.79M |
| September 23, 2026 | 1.005B |
| September 22, 2026 | 1.048B |
| September 21, 2026 | 997.46M |
| September 18, 2026 | 1.014B |
| September 17, 2026 | 997.46M |
| September 16, 2026 | 1.005B |
| September 15, 2026 | 1.011B |
| September 14, 2026 | 1.018B |
| September 11, 2026 | 1.002B |
| September 10, 2026 | 1.029B |
| September 09, 2026 | 1.130B |
| September 08, 2026 | 1.157B |
| Date | Value |
|---|---|
| September 04, 2026 | 1.180B |
| September 03, 2026 | 1.201B |
| September 02, 2026 | 1.259B |
| September 01, 2026 | 1.233B |
| August 31, 2026 | 1.202B |
| August 28, 2026 | 1.218B |
| August 27, 2026 | 1.227B |
| August 26, 2026 | 1.250B |
| August 25, 2026 | 1.244B |
| August 24, 2026 | 1.152B |
| August 21, 2026 | 1.157B |
| August 20, 2026 | 1.097B |
| August 19, 2026 | 1.160B |
| August 18, 2026 | 1.225B |
| August 17, 2026 | 1.145B |
| August 14, 2026 | 1.174B |
| August 13, 2026 | 1.192B |
| August 12, 2026 | 1.196B |
| August 11, 2026 | 1.063B |
| August 10, 2026 | 1.065B |
| August 07, 2026 | 929.44M |
| August 06, 2026 | 996.62M |
| August 05, 2026 | 910.12M |
| August 04, 2026 | 917.68M |
| August 03, 2026 | 916.84M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kalaris Therapeutics, Inc. | -38.34M |
| Arrowhead Pharmaceuticals, Inc. | 8.346B |
| Oncolytics Biotech, Inc. | 55.32M |
| Sangamo Therapeutics, Inc. | 53.89M |
| Sarepta Therapeutics, Inc. | 2.099B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -69.77M |
| Total Expenses (Quarterly) | 69.77M |
| EPS Diluted (Quarterly) | -0.7202 |
| Earnings Yield | -25.09% |
| Normalized Earnings Yield | -25.09 |